Table 2.
Characteristics including previous treatment and hormone substitution in 23 patients with acromegaly.
| Patients (n = 23) | |
|---|---|
| Median (range) | |
| Men/women (n) | 10/13 |
| Current age (years) | 68.5 (34–81) |
| Age at diagnosis (years) | 49.5 (28–72) |
| Years since diagnosis | 13.5 (1–38) |
| Surgery (no of patients) | 16 |
| Surgery (quantity/patient) | 1 (0–5) |
| Radiotherapy (n) | 3 |
| Somatostatin therapy (n) | 22 |
| Duration of somatostatin therapy (years) | 13 (1–27) |
| Dopaminagonist (n) | 5 |
| GH-receptor antagonist (n) | 2 |
| GH therapy (n) | 0 |
| Testosterone substitution (n) | 4 |
| Thyroxine substitution (n) | 4 |
| Cortisone substitution (n) | 3 |
| Hypertension (n) | 15 |
| Diabetes type 2 (n) | 3 |
| Cardiac failure | 1 |
GH, growth hormone; n, numbers.
This work is licensed under a